---
figid: PMC7434793__11523_2020_735_Fig1_HTML
figlink: pmc/articles/PMC7434793/figure/Fig1/
number: F1
caption: Mechanisms of resistance to BRAF-targeted therapy. V600E and KIAA1549-BRAF
  fusion lead to constitutive activation of MAPK signaling in tumor cells. MAPK phosphorylates
  downstream nuclear effectors that ultimately enhance cell survival and proliferation.
  One recognized mechanism of resistance to BRAF inhibition is the upregulation of
  CRAF, which activates MAPK through MEK. Concurrent inhibition of MEK overcomes this
  resistance. Both RAF and MEK inhibition, as well as EGFR gain-of-function mutation
  contribute to amplification of the PI3K/AKT/mTOR pathway that represents another
  mechanism of resistance to BRAF-targeted therapy. EGF epidermal growth factor, EGFR
  epidermal growth factor receptor, MAPK mitogen-activated protein kinase, MEK MAPK
  kinase, mTOR mammalian target of rapamycin, PI3K phosphoinositide 3-kinase, RAS
  rat sarcoma protein
pmcid: PMC7434793
papertitle: Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with
  a Focus on a Novel Management Algorithm.
reftext: Adam Kowalewski, et al. Target Oncol. 2020;15(4):531-540.
pmc_ranked_result_index: '74221'
pathway_score: 0.8955831
filename: 11523_2020_735_Fig1_HTML.jpg
figtitle: Resistance to BRAF-targeted therapy
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7434793__11523_2020_735_Fig1_HTML.html
  '@type': Dataset
  description: Mechanisms of resistance to BRAF-targeted therapy. V600E and KIAA1549-BRAF
    fusion lead to constitutive activation of MAPK signaling in tumor cells. MAPK
    phosphorylates downstream nuclear effectors that ultimately enhance cell survival
    and proliferation. One recognized mechanism of resistance to BRAF inhibition is
    the upregulation of CRAF, which activates MAPK through MEK. Concurrent inhibition
    of MEK overcomes this resistance. Both RAF and MEK inhibition, as well as EGFR
    gain-of-function mutation contribute to amplification of the PI3K/AKT/mTOR pathway
    that represents another mechanism of resistance to BRAF-targeted therapy. EGF
    epidermal growth factor, EGFR epidermal growth factor receptor, MAPK mitogen-activated
    protein kinase, MEK MAPK kinase, mTOR mammalian target of rapamycin, PI3K phosphoinositide
    3-kinase, RAS rat sarcoma protein
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGF
  - EGFR
  - BRAF
  - KIAA1549
  - HRAS
  - KRAS
  - NRAS
  - RAF1
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - MAP2K1
  - MAP2K2
  - AKT2
  - AKT3
  - AKT1
  - MAPK14
  - MAPK3
  - MAPK8
  - MAPK11
  - MAPK13
  - MAPK12
  - MAPK1
  - MAPK9
  - MAPK10
  - MAK
  - MTOR
  - Dabrafenib
  - Vemurafenib
  - Trametinib
  - Selumetinib
genes:
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: KIAA1549-
  symbol: KIAA1549
  source: hgnc_symbol
  hgnc_symbol: KIAA1549
  entrez: '57670'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: CRAF
  symbol: CRAF
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: МАРК
  symbol: MAK
  source: hgnc_symbol
  hgnc_symbol: MAK
  entrez: '4117'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
chemicals:
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Selumetinib
  source: MESH
  identifier: C517975
diseases: []
figid_alias: PMC7434793__F1
redirect_from: /figures/PMC7434793__F1
figtype: Figure
---
